MX364232B - Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular.. - Google Patents

Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular..

Info

Publication number
MX364232B
MX364232B MX2015000777A MX2015000777A MX364232B MX 364232 B MX364232 B MX 364232B MX 2015000777 A MX2015000777 A MX 2015000777A MX 2015000777 A MX2015000777 A MX 2015000777A MX 364232 B MX364232 B MX 364232B
Authority
MX
Mexico
Prior art keywords
macular degeneration
baclofen
based therapy
degeneration disorders
acamprosate
Prior art date
Application number
MX2015000777A
Other languages
English (en)
Other versions
MX2015000777A (es
Inventor
Cohen Daniel
Chumakov Ilya
Nabirochkin Serguei
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of MX2015000777A publication Critical patent/MX2015000777A/es
Publication of MX364232B publication Critical patent/MX364232B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a combinaciones y procedimientos para el tratamiento de transtornos de degeneración macular. Más específicamente, la presente invención se refiere a novedosas terapias de combinación de degeneración macular senil basadas en la combinación de baclofeno y acamprosato.
MX2015000777A 2012-07-18 2013-07-18 Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular.. MX364232B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (2)

Publication Number Publication Date
MX2015000777A MX2015000777A (es) 2015-10-14
MX364232B true MX364232B (es) 2019-04-16

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000777A MX364232B (es) 2012-07-18 2013-07-18 Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular..

Country Status (18)

Country Link
US (1) US9545389B2 (es)
EP (1) EP2874617B1 (es)
JP (1) JP6271539B2 (es)
KR (1) KR20150058159A (es)
CN (1) CN104780917B (es)
AU (1) AU2013291970B2 (es)
BR (1) BR112015001090A2 (es)
CA (1) CA2879114A1 (es)
EA (1) EA029157B1 (es)
ES (1) ES2729208T3 (es)
HK (1) HK1209335A1 (es)
IL (1) IL236737B (es)
IN (1) IN2015DN00820A (es)
MX (1) MX364232B (es)
NZ (1) NZ704280A (es)
SG (1) SG11201500309VA (es)
WO (1) WO2014013025A1 (es)
ZA (1) ZA201500663B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2005019163A2 (en) 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
US7227028B2 (en) 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
ES2365574T3 (es) 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
US9308260B2 (en) * 2007-07-05 2016-04-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticonvulsive pharmaceutical compositions
CA2703831C (en) 2007-09-07 2013-04-16 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090118365A1 (en) * 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
EP2403486A1 (en) * 2009-03-03 2012-01-11 XenoPort, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
JP2012524065A (ja) 2009-04-17 2012-10-11 ゼノポート，インコーポレーテッド ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体
RS58114B1 (sr) * 2011-03-01 2019-02-28 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata

Also Published As

Publication number Publication date
KR20150058159A (ko) 2015-05-28
IL236737B (en) 2018-12-31
JP2015522601A (ja) 2015-08-06
IL236737A0 (en) 2015-02-26
EP2874617A1 (en) 2015-05-27
SG11201500309VA (en) 2015-02-27
MX2015000777A (es) 2015-10-14
JP6271539B2 (ja) 2018-01-31
ES2729208T3 (es) 2019-10-30
CA2879114A1 (en) 2014-01-23
EA029157B1 (ru) 2018-02-28
AU2013291970B2 (en) 2017-09-28
BR112015001090A2 (pt) 2017-06-27
US20150238452A1 (en) 2015-08-27
WO2014013025A1 (en) 2014-01-23
CN104780917B (zh) 2017-09-08
IN2015DN00820A (es) 2015-06-12
AU2013291970A1 (en) 2015-02-19
EA201500143A1 (ru) 2015-05-29
EP2874617B1 (en) 2019-02-27
CN104780917A (zh) 2015-07-15
ZA201500663B (en) 2016-10-26
HK1209335A1 (en) 2016-04-01
NZ704280A (en) 2017-06-30
US9545389B2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
IN2014DN00288A (es)
IN2014DN00286A (es)
IN2014MN00093A (es)
IN2014MN01378A (es)
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
IN2014DN06792A (es)
WO2013061161A3 (en) New combination therapies for treating neurological disorders
SG194718A1 (en) Novel compounds as modulators of protein kinases
AU2011328009A8 (en) Compounds and methods for treating pain
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
NZ704280A (en) Baclofen and acamprosate based therapy of macular degeneration disorders
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy

Legal Events

Date Code Title Description
FG Grant or registration